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Abstract
The recent FDA approval of the MiSeqDx platform provides a unique opportunity to develop
targeted next generation sequencing (NGS) panels for human disease, including cancer.
We have developed a scalable, targeted panel-based assay termed UNCseq, which in-
volves a NGS panel of over 200 cancer-associated genes and a standardized downstream
bioinformatics pipeline for detection of single nucleotide variations (SNV) as well as small in-
sertions and deletions (indel). In addition, we developed a novel algorithm, NGScopy, de-
signed for samples with sparse sequencing coverage to detect large-scale copy number
variations (CNV), similar to human SNP Array 6.0 as well as small-scale intragenic CNV.
Overall, we applied this assay to 100 snap-frozen lung cancer specimens lacking same-pa-
tient germline DNA (07–0120 tissue cohort) and validated our results against Sanger se-
quencing, SNP Array, and our recently published integrated DNA-seq/RNA-seq assay,
UNCqeR, where RNA-seq of same-patient tumor specimens confirmed SNV detected by
DNA-seq, if RNA-seq coverage depth was adequate. In addition, we applied the UNCseq
assay on an independent lung cancer tumor tissue collection with available same-patient
germline DNA (11–1115 tissue cohort) and confirmed mutations using assays performed in
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a CLIA-certified laboratory. We conclude that UNCseq can identify SNV, indel, and CNV in
tumor specimens lacking germline DNA in a cost-efficient fashion.
Introduction
Use of next generation sequencing (NGS) for large-scale analysis of DNA sequence alterations
in human tissue, which may be related to etiopathogenesis of disease, is not only useful in basic
science studies, but is now an established laboratory technique used in clinical medicine, in par-
ticular for the care, of patients with distant metastatic cancer (reviewed in [1]). Implementation
of NGS as a standard clinical laboratory test is the next logical step following FDA approval of
several first generation sequencing-based companion diagnostic tests over the last decade that
refine the use of targeted gene variants for managing distinct cancer subtypes. In line with FDA
approval of the MiSeqDx platform in November 2013, targeted panel sequencing (TPS) is the
next step towards implementing affordable, small-scale, NGS-based laboratory diagnostics [2].
FDA approval of a generic platform for NGS has encouraged individual laboratories to ad-
dress the inherent challenges associated with development of such tests. These challenges in-
volve fiscal matters, issues in methodology and optimal bioinformatics pipelines that offer a
reasonable compromise between technical sophistication and time efficiency. Since various lab-
oratories address such matters differently, dissemination of information regarding methods
and performance characteristics of a particular NGS-based laboratory assay is a basis for dis-
cussion and evaluation of strengths and weaknesses by the scientific community.
In line with this, an increasing number of reports of NGS-based laboratory methods to ana-
lyze clinical tumor specimens by different laboratories for clinical decision were recently pub-
lished [1, 3–8]. At the University of North Carolina at Chapel Hill (UNC-CH), we developed a
scalable NGS assay (UNCseq) that involves TPS of DNA obtained from tumor and matched
non-malignant specimens for a gene panel (ClinSeq) of over 200 cancer-associated genes that
were selected and updated quarterly by UNC Committee for the Communication of Genetic
Research Results (CCGR). In addition, UNCseq developed a standardized downstream bioin-
formatics pipeline, which is currently being used to order confirmatory tests for reporting clini-
cally ‘actionable’ genetic events to the treating physician under an Institutional Review Board
(IRB)-approved study (Fig 1). In this report, we test our ability to successfully perform Illumina
HiSeq 2000 sequencing upon DNA extracted from tumor specimens from patients with lung
cancer, in particular, the non-small cell lung cancer (NSCLC) subtype. In addition, we summa-
rize our experience in sample acquisition, pathologist-vetted tumor diagnosis, DNA extraction,
NGS, and analytical validation of genetic results. Finally, we provide our experience of applying
this NGS-based assay in reporting somatic mutations from ‘real-world’ samples—both snap-
frozen (SF) and formalin-fixed and paraffin-embedded (FFPE)—for diagnostic purposes with
validation of results in a CLIA-certified laboratory. We confirmed that TPS in a well annotated
lung cancer cohort is not only a more sensitive method than Sanger sequencing in SNV detec-
tion, but also more specific to identify genetic aberrations in known cancer-related genes with
important prognostic and treatment implications. By performing deep sequencing of cDNA
prepared from RNA (RNA-seq) in a subset of these samples, we also confirmed several SNV
detected by the sequencing of DNA (DNA-seq), depending on the coverage depth by RNA-seq
and the mutant allele frequency (MAF) by DNA-seq. Given the fact that matched normal
DNAmay not always be available, we provide systematic comparison of SNV calling algo-
rithms using matched germline versus pooled normal DNA, and versus mere tumor
DNA/RNA-Based Next Generation Sequencing in NSCLC Samples
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Fig 1. The UNCseq project. (A) The UNCseq project is an initiative that involves clinicians and patients
interested to participate in a non-therapeutic clinical trial conducted through the Lineberger Comprehensive
Cancer Center (IRB-approved protocol 11–1115), as well as a multidisciplinary team that involves clinical and
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genotyping in a subset of those specimens. Finally, we present a new algorithm, NGScopy
(http://www.bioconductor.org/packages/release/bioc/html/NGScopy.html), to detect genome-
wide CNV using TPS data. We conclude that our NGS-based laboratory assay is sensitive, yet
specific, cost-effective, robust, and standardized, and facilitates downstream bioinformatics
analysis to assess SNV, indel, and CNV in a time-efficient and clinically impactful manner.
Materials and Methods
Patients, Tumors, and Histopathologic Assessment
Under the IRB and Office of Human Research Ethics, The University of North Carolina at
Chapel Hill (UNC-CH), approved protocol 07–0120, patients who underwent standard of care
(SOC) surgery for primary lung cancer were identified, followed by retrieval of SF, banked
tumor tissues (07–0120 tumor tissue cohort; n = 100). A separate cohort of patients with lung
cancer who had become refractory to standard systemic treatments was consented under the
IRB and Office of Human Ethics, UNC-CH approved protocol 11–1115 (11–1115 tumor tissue
cohort; n = 24). Written informed consent from the subject patients was obtained for the use of
these samples in research. The 11–1115 protocol allows for TPS of SF or archived FFPE tumor
tissues and same-patient germline DNA to identify genetic aberrations of prognostic or thera-
peutic significance using the UNCseq assay. Genetic aberrations that are identified under the
UNCseq assay and have potential clinical significance are then subjected to validation in a
CLIA-certified laboratory only for the 11–1115 tumor tissue cohort (Fig 1). In addition, tumor
content for each specimen of both cohorts was estimated based on routine microscopic analysis
of representative hematoxylin and eosin (H&E)-stained sections from adjacent tumor by a pa-
thologist (XY) who was blind to patient history.
DNA Library Preparation and Capture
5 μm-thick tissue sections were prepared from SF or FFPE tumor tissues. DNA was isolated
using the Gentra Puregene Tissue Kit (QIAGEN, Valencia, CA). 3 μg of DNA was then sheared
for 60–90 seconds using the Covaris ultrasonicator instrument (E220) following manufacturer
instructions (Covaris Inc., Woburn, MA). Non strand-specific DNA library preparation was
performed using an Agilent SureSelectXT Reagent kit with custom target enrichment following
manufacturer’s recommendations (Agilent Technologies Inc., Santa Clara, CA). DNA was then
subjected to repair, end-polishing (blunt-end or A-overhang), and ligation of custom, single-
end adapters. Libraries were then captured with biotinylated RNA baits designed by Agilent
Technologies to separate exonic sequences for a consensus list of genes associated with cancer.
More specifically, the genes were selected by UNC CCGR from publications and from the peri-
odically updated Catalogue of Somatic Mutations in Cancer (COSMIC) database [9], based on
the frequency of mutation(s) in solid tumors, their potential role in oncogenic pathways, and
research faculty (medical oncologists, pathologists, bioinformaticians, and molecular biologists) who
generate, critically assess, and discuss NGS data in relation to patients’ clinical history and review previously
identified genetic aberrations to determine which are potentially clinically actionable and targeted for
downstream validation using validated methods in a CLIA-certified laboratory. (B) Following consent to 11–
1115, tumor tissues and peripheral blood are collected from cancer patients. Hematoxylin and eosin (H&E)-
stained representative tissue sections from tumor samples (SF or FFPE) are assessed by a certified
pathologist for the percentage of viable tumor/stroma content and presence/absence of necrosis (sample
QC). Extracted DNA from tumor samples is processed through various steps (fragmentation, DNA library
preparation, in-solution capture of DNA fragments of interest, small-scale amplification of captured DNA
fragments) prior to Illumina NGS. Data generated are discussed in a multidisciplinary Molecular Tumor Board
meeting. Following validation in a CLIA-certified laboratory, these genetic aberrations are reported in
patients’ personal electronic medical records.
doi:10.1371/journal.pone.0129280.g001
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their potential relevance of antitumor response to small molecule inhibitors. This gene list is
updated on a quarterly basis by the UNC CCGR according to new research and medical find-
ings [UNCseq ClinSeq versions 4, 5 (07–0120 tumor tissue cohort), and version 7 (11–1115
tumor tissue cohort); S1 Table]. A set of genomic region targets that cover all exons for each
gene was developed based on the University of California at Santa Cruz (UCSC) Known Gene
database [10, 11]. Regions of the targeted exons for capture were extended to include 250 base
pairs (bp) of flanking sequences in intronic regions to comprehensively cover targeted genes.
These genomic locations provided the basis for the design of 120 nucleotide (nt) biotinylated
capture oligos for Agilent SureSelect capture using the Agilent eArray web portal (https://
earray.chem.agilent.com/suredesign/). Each kit targeted 3,379 (ClinSeq v4), 3,323 (ClinSeq v5),
or 5,997 (ClinSeq v7) regions spanning 2,231,841-bp for a total of 228 genes (ClinSeq v4),
3,451,622-bp for a total of 184 genes (ClinSeq v5), and 2,820,216-bp for a total of 248 genes
(ClinSeq v7) (S1 Table). Capture of barcoded-and-pooled or unpooled libraries was processed
by the Agilent SureSelect Protocol.
Prior to submission for NGS, DNA libraries were subjected to a three-step quality control
protocol. DNA concentration was measured using a Qubit 2.0 fluorometer (Life Technologies,
Grand Island, NY), DNA quality was assessed using Agilent’s 2100 Bioanalyzer high sensitivity
DNA assay, and DNA size was determined by the Experion automated electrophoresis system
(BioRad, Hercules, CA). A normalized molarity for each library was then calculated based on
DNA size and concentration. Libraries were pooled to include 2–8 samples per sequencing
lane. Each pool was diluted into 5.5 pM, as per the Illumina cBot Cluster Generation step. Clus-
ters were then generated using TruSeq SR Cluster Kit v.2 and were loaded into the HiSeq 2000
sequencer (Illumina Inc., San Diego, CA). Sequencing by synthesis [12] was performed using
standard single-indexed libraries on either single-read (07–0120) or paired-end (11–1115) flow
cells with 100 cycles (ClinSeq 1 x 100-bp or 2 x 100-bp, respectively) and an index read (‘bar-
code’) consisting of 7 cycles of sequencing using the Illumina TruSeq SBS v.3 chemistry. S2
Table summarizes key differences in sample processing and sequencing between the 07–0120
and 11–1115 tumor tissue cohorts.
DNA NGS Data Analysis Pipeline
Preprocessing, Pre-filtering, Alignment, and Filtering. The data analysis pipeline is
shown in Fig 1. No strand-bias was considered in any of the pre-processing steps. Raw se-
quence reads were analyzed using the CASAVA v.1.8 package (Illumina) to generate barcoded
reads and were reported as FASTQ files [13]. If applicable, reads were then subjected to quali-
ty-filtering and adapter-stripping using the FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_
toolkit/index.html). The Phred quality score of base calling (CallQ) of each nucleotide in a read
was then examined to determine whether to trim the read at the ends when a number of con-
tinuous nucleotides average per-base CallQ 20, or 99% accuracy. The raw sequence reads
in FASTQ files were then aligned to the Genome Reference Consortium human genome, build
37 (GRCh37; http://www.ncbi.nlm.nih.gov/assembly/GCF_000001405.13/), using either the
Burrows-Wheeler Aligner [14] (BWA 0.6.2) for the 07–0120 cohort or the BWA-MEM (ver-
sion 0.7.4) for 11–1115 cohort. Reads were then sorted and indexed using SAMtools (0.1.19-
44428cd) [15]. Local realignment and base quality score recalibration were performed using ei-
ther the Genome Analysis Toolkit (GATK 2.6) and the GATK resource bundle (2.5) [16] in
07–0120 cohort or the ABRA (0.46) [17] in 11–1115 cohort. Default parameter settings were
used with tools above. Mapped reads were further filtered by mapping quality before down-
stream analysis. Filtering was performed by imposing a minimum Phred quality score of read
mapping (MapQ). Reads with low mapping quality (MapQ< 5, i.e.< 70% accuracy) were
DNA/RNA-Based Next Generation Sequencing in NSCLC Samples
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removed. Median and approximate 95% confidence interval (approx. 95% CI) were calculated
for on-target reads for each tumor cohort and for each ClinSeq caption version. The median of
the per-sample median RPKM (reads per region kilobase per million targeted reads mapped)
[18] was used to describe the average reads per region.
Quality Control. Depth, breadth of coverage, and on-target rate were computed according
to definitions outlined in S1 Text.
Variant Calling. Due to the retrospective specimen collection of the 07–0120 tumor tissue
cohort, DNA from same-patient normal tissues (e.g., peripheral blood) was not available to ex-
tract germline DNA. For control DNA, we instead sequenced and pooled DNA that was ex-
tracted from 8 normal tissues (6 liver and 2 uterus from a total of 4 patients) under similar
conditions and treatment protocols applied to those for DNA-seq of tumor samples. Genetic
variants were called by deepSNV [19]. SNV calls from our assay were further refined using the
prior knowledge from a highly curated list of 41 genes with 279 SNV and 91 indel positions
that have been used by the OncoMap system (version 4; an expert curated source that we call
‘conservative’ list) [20] and the COSMIC database (version 66) with annotation in lung cancer
only. We call the COSMIC list ‘less-conservative’ as it consists of 18,722 genes with 250,741
SNV and 4,949 indel positions; 265 out of these 18,722 genes that have no genomic coordinate
information of the variants were excluded [9]. Of note, all genes and SNV/indel positions of
the OncoMap system are all annotated in the ‘less-conservative’ list, and therefore the latter is
also referred to as the OncoMap plus COSMIC system.
For variant calling on the 07–0120 tumor cohort, we defined significant SNV by filtering
each of the mutation calls using the ‘deepSNV’ package with Bonferroni-adjusted p-
value 0.001, MAF 0.005, mutant allele read count (MAC) in tumor 5, and the logarith-
mically transformed (log2) odds ratio (OR)[21] of MAC of each individual tumor sample ver-
sus the pool of normal samples 4. In other words, the odds of calling a SNV in each
individual tumor sample were 16 (i.e., 24) times higher compared to the pooled normal. We
selected this MAF threshold because it was at least two times higher than the previously re-
ported sequencing error of approximately 0.001–0.002 [22]. Regarding the MAC threshold, we
arbitrarily set it to 5, which is more strict than MAC> 2 that was previously reported [23]. Fil-
tered SNVs were annotated by ANOVAR (2014.07.14). To improve confidence in calling un-
matched tumors, SNV were further refined using the ‘conservative’ list [24] as well as the ‘less-
conservative’ list.
Based on gene-wise aggregation of the significant SNV identified above, each individual
gene was then tested under the null hypothesis that the mutation rate across the gene is in ac-
cordance with the background mutation rate, to obtain a p-value using a conventional binomial
probability model [25] to adjust mutation rates for gene length. Finally, the SMG were reported
using the significant level of mutated genes for all tested genes with false discovery rate (FDR)
 0.05. Indel were called by VarScan (2.3.6) with default setting.
Variant calling of the 11–1115 tumor tissue samples was performed by the updated ver-
sion of the UNCseq pipeline (August 2014). More specifically, we used the strelka somatic
variant caller (2013) with default settings [26] to detect both SNV and indel with quality
scores of at least 30 for both, ANOVAR (version 2014.07.14) to annotate detected variants,
and SAMtools/BCFtools (version 0.1.19-44428cd) for normal-free variant calling. To estab-
lish a ‘contemporary pooled’ normal DNA for this tumor tissue cohort, we first generated a
‘leave-one-out’ pooled DNA consisting of all sequenced reads from the available germline
DNA of the 11–1115 cohort, excluding the matched germline DNA for the particular sample.
In other words, for a given i-th tumor sample, the pooled normal consisted of 23 normal
DNA/RNA-Based Next Generation Sequencing in NSCLC Samples
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samples from patients 1, 2, . . ., i-1, i+1, . . .,n (n = 24). As a second step, we subsampled the
total reads from the pooled normal DNA to reduce the computational time, and generated a
comparable size of contemporary library for optimal statistical analysis. The S2 Table sum-
marizes key differences in bioinformatics analysis between the 07–0120 and 11–1115 tumor
tissue cohorts.
Detection of Copy Number Variations. We calculated chromosome-level copy number
variations (CNV) in the 07–0120 tumor tissue cohort using the read depth. Due to the inher-
ently heterogeneous, interrupted coverage of the genome by TPS, we employed a ‘restriction-
imposed,’ flexible windowing algorithm to ensure a balanced number of reads per window
across the entire genome in the R/Bioconductor package NGScopy (1.0.0). To enable detec-
tion of copy number in both targeted and off-targeted areas of the genome, which usually
have high and low coverage depth, respectively, off-target reads (‘background reads’) were
used in addition to on-target. Two criteria defined such a flexible window. First, to ensure
even variance as well as adequate number of reads per window, the read depth per window
in the pooled normal control sample was no less than 20x per sample. Second, its minimal
window size was kept within a range determined by coverage characteristics, as in genomic
regions with high-read density, the use of small window sizes leads to a ‘sawtooth,’ under-
smoothened signal. For this study, the minimum window size used was 20 Kbp. Library size-
normalized reads per window for both pooled normal control and each tumor sample were
counted to compute the tumor/normal log2 copy number ratio (CNR) as the relative copy
number. To account for copy number neutrality, we normalized our data per tumor sample
by centering the median of the relative copy numbers to zero across the entire genome. Direct
visualization was used to assess structural variations across the genome. Finally, segmenta-
tion was performed by a heterogeneous hidden Markov model, termed BioHMM [27], which
was adapted for NGS data.
To calculate gene-level CNV in the 07–0120 tumor tissue cohort, we used the depth of gene
exon-specific sequenced reads with 1-bp resolution. We estimated the relative copy number,
similarly as above, by computing the log2 ratio of the per-base read depth of the tumor versus
the pooled normal control.
Validation of DNA NGS Data by RNA Sequencing. Agilent strand-specific RNA with
capture was performed for preparation. RNA sequencing (RNA-seq) whole-transcriptome
analysis in a subset of tumor samples from the 07–0120 tumor tissue cohort was performed on
Illumina GAII as previously described [28, 29]. The full 76-bp, single-end reads were first
aligned to the human reference genome (hg19) by MapSplice [30]. SNV called by DNA-seq
were subsequently validated by analysis of RNA-seq data using two independent mutation call-
ing algorithms: the SAMtools (mpileup command)/BCFtools [15] and our recently published
RNAseq-specific mutation calling method, UNCeqR [31].
DNA Non-NGS Assays. For the 07–0120 tumor tissue cohort, we have previously per-
formed Sanger sequencing using a DNA analyzer (ABI 3730xl, Applied Biosystems, Foster
City, CA) for mutation detection of selected exons of the KRAS gene as well as selected exons
of the genes BRAF, CDKN2A, EGFR, STK11, and TP53. In addition, samples from the 07–0120
cohort were subjected to analysis using the Genome-Wide Human SNP Array 6.0 microarray
(Affymetrix, Santa Clara, CA) for detecting CNV in a subset of our lung cancer samples [32].
SNP array analysis for CNV was performed using the open source R package aroma.affymetrix
version 2.5.0 (http://cran.r-project.org/web/packages/aroma.affymetrix) and DNACopy ver-
sion 1.30.0 (http://www.bioconductor.org/packages/release/bioc/html/DNAcopy.html) for
data processing and CNV analysis, respectively.
Confidence Interval for a Median. Confidence interval (CI) for a median was calculated
as previously described [33].
DNA/RNA-Based Next Generation Sequencing in NSCLC Samples
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Results
Clinicopathologic Characteristics of the 07–0120 and 11–1115 Patient
Samples
Tumor tissues from 100 and 24 patients with primary lung cancer were included in the analysis
for the 07–0120 and 11–1115 tumor tissue cohorts, respectively. Clinicopathologic characteris-
tics for each cohort are shown in Table 1. Targeted panel capture using ClinSeq versions 4 and
5 were performed in 64 and 36 of the 07–0120 SF samples, respectively, and ClinSeq version 7
was applied to all 24 tumor samples from the 11–1115 tumor tissue cohort. Pooled normal
DNA was available for analysis of the 07–0120 tumor cohort, whereas matched germline DNA
was available for the 11–1115 tumor cohort. S1 Table shows the list of genes whose exons were
sequenced as part of ClinSeq versions 4, 5, and 7.
Bioinformatics Analysis of the 07–0120 Patient Samples
We obtained a total of 2,100,991,292 reads from all 64 samples that were sequenced using the
ClinSeq version 4, and 591,549,582 reads from all 36 samples that were sequenced using the
ClinSeq version 5. All samples have passed quality control using the FASTX-Toolkit.
93.96 ± 0.85% of these reads were uniquely mapped to the reference genome with MapQ 5,
i.e. 1,985,916,272 (94.5%) and 551,493,714 (93.2%) for ClinSeq 4 and 5, respectively. The medi-
an number of uniquely mapped (mapQ 5) reads per sample was 18,171,425 (approx. 95CI
16,442,697–27,015,601) and 14,350,546 (approx. 95CI, 13,786,985–15,363,758) for samples se-
quenced in ClinSeq versions 4 and 5, respectively. We were able to retrieve 71.6% (median;
approx. 95CI, 70.9%-72.5%) and 30.6% (median; approx. 95CI, 29.9–31.4%) on-target bases
with our targeted panel capture strategy for ClinSeq version 4 and 5, respectively. The switch
from ClinSeq version 4 to 5 was associated with several changes, including ad hoc design of
primers by the investigators, as opposed to the vendor (Agilent), as well as new genomic re-
gions of interest whose capture efficiency and ability to readily sequence were questionable.
The median of the per-sample median RPKM was 452 (approx. 95CI, 448–458) and 446
(approx. 95CI, 440–454) for samples sequenced using the ClinSeq version 4 and 5, respectively.
SNV/indel analysis was restricted to the shared DNA regions for ClinSeq versions 4 and 5,
1,190,667 bases per sample, or 168 genes, for comparison among samples. For copy number
analysis, the entire genome was considered, either on-target or not.
A common strategy to overcome the intrinsic high error rate of NGS instruments and to en-
sure the adequate coverage of both alleles for each variant site or the existence of multiple clones
is to ideally sequence individual genomes to 20-30x coverage depth [34]. Such coverage depth is
sufficient for a normal tissue, a genetically homogeneous cancer tissue, such as cancer cell lines,
or tumor tissue with minimal stromal ‘contamination,’ but not for tumor tissues with variable
degree of cellular and/or molecular heterogeneity (i.e., subclones of varying genotype) (Fig 1). A
recent study showed that a 30x coverage depth was sufficient for an approximate 90% sensitivity
to call mutations at allele fractions of 0.2 [35]. For the latter cases, a minimum of 50x coverage
depth is commonly used to call single nucleotide or other genetic variants.
To establish the optimal balance between cost and coverage depth for our TPS strategy, we
sequenced 2 (n = 24 samples), 4 (n = 4), or 8 samples (n = 72) per flowcell lane. As shown in
Fig 2, a target overall coverage depth of 50x was reached when up to 8 samples per lane were
loaded. The mean percentages of on-target bases having no less than 50x coverage depth for 2,
4, and 8 samples per lane are 98%, 95%, 93%, respectively; and 97%, 92%, 86%, respectively, for
no less than 100x depth. We conclude that 8 samples per lane provide sufficient cost- and
time-effective coverage (50x) under our TPS strategy.
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Comparison in SNV Calling Between NGS and Sanger Sequencing in
the 07–0120 Patient Samples
To assess whether NGS is at least as sensitive as Sanger sequencing in SNV calling for known
mutation hotspots, we compared results for detection of KRAS hot-spot SNV between the two
sequencing platforms. We selected KRAS for this investigation because it bears indisputable
Table 1. Clinicopathologic characteristics of lung cancer specimens for the 07–0120 and 11–1115 tumor tissue cohorts.











Current/Former Smoker 74 20




Squamous Cell Carcinoma 31 4
Adenocarcinoma or Bronchoalveolar 50 18
Large Cell Carcinoma 7 0
Adenosquamous Carcinoma 7 0
Carcinoid 4 0














% Tumor in H&E (Mean, Range) 78 (10–100) 50 (15–90)
Mutations by Sanger Sequencing (07–0120 tumor cohort only) No Call No Mutation Mutation Identified
KRAS 0 91 9
TP53 12 58 30
EGFR 30 64 6
STK11/LKB1 6 88 6
doi:10.1371/journal.pone.0129280.t001
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hotspot somatic SNV for lung cancer in codons 12 and 13, which have been previously well
identified [36, 37]. As shown in Fig 3, panels A and B, using our NGS pipeline, we detected all
8 hotspot SNV identified by Sanger sequencing. Furthermore, 8 additional hotspot SNV not
identified by Sanger sequencing were also called by our NGS pipeline. As shown in Fig 3, panel
C, neither low NGS coverage nor low tumor purity was different between the 8 agreed and the
8 discrepant cases by NGS and Sanger sequencing (p-value> 0.1, two-sided Wilcoxon test).
Compared to Sanger sequencing, NGS was able to detect the KRASmutant alleles with signifi-
cantly lower MAF (p-value = 0.0006, two-sided Wilcoxon test; Fig 3, panel C). Interestingly,
the MAF of 4 discrepant cases (ID: 30, 65, 72, 60) are below but close to 0.20, implying that
Sander sequencing is less sensitive to detect SNV with MAF 0.20, in accordance with previ-
ous reports [38]. The MAF of the other 4 discrepant cases (ID: 97,56,38,70) are close to 0.05 or
below, indicating NGS was able to capture SNV with very low MAF.
To assess the sensitivity of our NGS SNV calling algorithm, we focused on the first coding
exon of KRAS (RefGene ID: NM_033360). This 111-bp DNA region (chr12:25,398,208–
25,398,318) contains the 6-bp positions corresponding to the hotspot sites in codons 12 and 13
(chr12:25,398,280–25,398,285). Of the remaining 105 bp, there are 52-bp positions with vari-
ants annotated by OncoMap plus COSMIC system or dbSNP, and 53-bp positions without var-
iants annotated by either OncoMap plus COSMIC system or dbSNP [39]. Using our SNV
calling algorithm, we detected all 9 SNV (8 hotspot SNV as reported above plus 1 SNV at
chr12:25398262 of Sample ID: 98) that were independently detected by Sanger sequencing, in-
dicating that NGS is not less sensitive in detecting SNV compared to Sanger sequencing. To
evaluate possible false positives, we assume that positive calls falling in the 53-bp annotation-
free regions are likely false. Only two possible false positive calls (0.04%) by NGS across all 100
samples (53-bp positions per sample x 100 samples = 5,300 bases) were detected. We conclude
that, at least for the first coding exon of the KRAS gene, NGS is sensitive to identify true SNV
while not generating a substantial number of false positives. Since both true positives and true
negatives of somatic SNV in our tumor specimens are unknown, defining the actual sensitivity
and specificity is left as an open question [40,41].
To further extend our findings about the sensitivity of NGS to detect mutations detected by
Sanger sequencing, we analyzed a second gene TP53 that has reported SNV distributed much
more broadly than KRAS. Within the 544-bp region that harbors TP53 (RefGene ID:
NM_000546) exons 5, 6, 7, and 8, 317-bp positions have been annotated as variants by Onco-
Map plus COSMIC system or dbSNP, whereas 227-bp positions have no such annotation. Sim-
ilar to the case of KRAS, we detected all 30 SNV that were independently detected by Sanger
sequencing and only 20 possible false positive calls in the 227-bp annotation-free positions
Fig 2. Depth and Breadth of On-Target Coverage of the 100 Lung Cancer Samples. Shown for each tumor specimen is the percentage of targeted bases
covered at given coverage depth (1x, 20x, 50x, 100x) and sequenced under different lane settings in the HiSeq 2000 instrument (2, 4, and 8 DNA libraries per
lane, Lib/Ln).
doi:10.1371/journal.pone.0129280.g002
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across all 100 samples (227 variant-free bp positions per sample x 100 samples = 22,700 bases).
Interestingly, one of these 20 positive calls (Sample ID: 4 at chr17:7578538, TP53:NM_000546:
exon5:c.A392T) was confirmed by Sanger sequencing to be a true positive. Although this posi-
tion is not annotated for any SNV in lung by the COSMIC database (v66 or v72, the latest ver-
sion during paper preparation) nor dbSNP, it is annotated in other cancer types, such as breast,
central nervous system, liver, pancreas, and the upper aerodigestive and urinary tracts (COS-
MIC, v72). The other 19 calls have no Sanger sequencing data and are possible false positives
(0.08%).
Identification of Other Coexistent SNV and Indel by NGS
The power of NGS is the ability to detect genetic aberrations in large sets of genes, or even the
entire genome, in a cost-effective fashion. We examined SNV in the 168 targeted genes that
were consistently captured in both versions of our assay. Due to lack of matched germline in-
formation from our cases, we used prior knowledge from existing SNV annotation databases to
refine mutations called using pooled normal. As shown in Fig 4 and using the deepSNV muta-
tion calling method in OncoMap system, we detected 22 genes that were found to be signifi-
cantly mutated (FDR 0.05) in our dataset (overall 101 mutations, approximately one SNV
per sample). 49 tumor samples did not have any mutations in any of the 22 genes. 9 genes were
the most frequently mutated (KRAS, TP53, EGFR, PIK3CA, BRAF, NRAS, JAK3, CTNNB1,
CDKN2A) whereas 19 genes from the OncoMap database showed no SNV (ABL1, AKT2, APC,
CDK4, CSF1R, FGFR2, FLT3, GNA11, GNAQ, GNAS, IDH1, JAK2,MLH1,MYC, NPM1,
PDGFRA, PIK3R1, RET, SRC). Similar refined gene lists were obtained with VarScan2 (version
2.3.6) [42], and MuTect (version 1.1.4) [35]. The concordance rate for mutations within the
OncoMap plus COSMIC system among deepSNV, MuTect, and VarScan2 was 100% (data not
Fig 3. SNV Calling ofKRASHotspots Using First- and Next-Generation Sequencing. (A) Sequencing chromatograms (Finch TV trace viewer v1.4.0)
obtained from two tumor tissue examples showing concordance (sample 24) or discordance (sample 38) in KRAS SNV calling. (B) SNV calling at hot-spot
loci in KRAS codon 12 and 13 for all 16 tumors using either of the two sequencing strategies. Calls by Sanger and NGS are colored in orange and blue,
respectively. Calls by both platforms are colored in half orange and half blue. NGS coverage depth, purity, and MAF are also shown. (C) Boxplots of MAF,
tumor purity, and coverage depth between discordant and concordant SNV calls are shown (p-value = 0.0006, two-sided Wilcoxon test).
doi:10.1371/journal.pone.0129280.g003
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shown). Given the fact that we have performed Sanger sequencing in selected exons in a limited
number of genes (BRAF, CDKN2A, EGFR, STK11, TP53) we have been unable to confirm
indels identified by NGS.
Using the pooled normal control to identify SNV in our tumor samples against the ‘less-
conservative’ list, we identified 42 significantly mutated genes (FDR 0.05) out of the total
168 targeted genes (S1 Fig). Remarkable was the hypermutated tumor (39 mutations) from pa-
tient 1 who was a smoker and had mutation in two DNA repair genes, as previously described
[43]. Interestingly, a higher fraction of non-synonymous SNV was identified in OncoMap sys-
tem (95/101 = 94.1% non-synonymous out of all polymorphisms) compared to OncoMap plus
COSMIC system (292/364 = 80.2% non-synonymous out of all polymorphisms), indicating
that the OncoMap system focuses more on functional-important variants. As shown in
Table 2, the majority of genes that were previously shown to have non-synonymous SNV in
previously published large datasets for lung squamous and lung adenocarcinoma [44, 45] were
also present in our cohort using the OncoMap and COSMIC systems. In addition, new non-
synonymous SNV were identified that were not previously described for both systems. Howev-
er, we observed significantly lower frequency of SNV calling between OncoMap and the pub-
lished datasets by individually comparing SNV call by OncoMap with those by each of the two
published datasets. We obtained p-value< 0.05 in both comparison by paired permutation
tests with exact p-value using the R function perm.test from the open source R package
Fig 4. SNV Calling in Lung Cancer Specimens Using the UNCseq Assay for SNV Listed in the OncoMap System (‘Conservative’ SNV). Percentage,
actual number of significantly mutated genes, and particular SNV types, nonsynonymous (nonsense, missense) and synonymous, are shown for each tumor
sample in relation to its tumor histology and tumor purity. Abbreviations: SqCC: Squamous Cell Carcinoma; SmCC: Small Cell Carcinoma; ADC/BAC:
Adenocarcinoma or Bronchio-alveolar Carcinoma; LCC: Large Cell Carcinoma; AD-SqC: Adenosquamous Carcinoma or Combined/Mixed; Carcinoid/
NSmCC: Carcinoid-Atypical, Carcinoid-Typical, or Non-small cell carcinoma.
doi:10.1371/journal.pone.0129280.g004
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exactRankTests (http://cran.r-project.org/package=exactRankTests), under the null hypothesis
that SNV calls are identically distributed for each SMG between OncoMap and the published
dataset.
Indel analysis showed 23 deletions (14 nonframeshift and 9 frameshift) and no insertions.
As shown in S1 Fig, we observed recurrent nonframeshift deletions in the ARID4B gene
(chr1:235377279–235377281, p.548_549del), which have not been previously reported. These
Table 2. SNV Calling (07–0120 Cohort) Using Two Different SNV Databases (OncoMap ± COSMIC) for the 2 most frequent histologic lung cancer
types, adenocarcinoma and squamous carcinoma.
Adenocarcinoma N = 50 OncoMap (%) OncoMap plus COSMIC (%) Imielinski Et Al (%)
TP53 16 42 52
KRAS 26 28 27
EGFR 10 22 19
STK11 4 18 15
KEAP1 N/A N/A 12
ATM N/A 10 11
NF1 N/A 12 14
SMARCA4 N/A 8 13
ARID1A N/A 0 9
BRAF 4 4 8
RBM10 N/A N/A 7
SETD2 N/A 0 5
PIK3CA 10 18 5
CBL N/A 0 4
FBXW7 N/A 16 4
PPP2R1A N/A 0 4
RB1 6 12 3
SMAD4 N/A 8 4
CTNNB1 6 10 3
U2AF1 N/A 0 3
KIAA0427 N/A N/A 2
PTEN 4 8 3
BRD3 N/A N/A 2
FGFR3 2 0 2
GOPC N/A 0 1
Squamous Cell N = 31 OncoMap (%) OncoMap plus COSMIC (%) TCGA (%)
TP53 6 55 81
CDKN2A 0 3 15
PTEN 0 0 8
PIK3CA 6 10 16
KEAP1 N/A N/A 12
MLL2 N/A 0 20
HLA-A N/A N/A 3
NFE2L2 N/A 10 15
NOTCH1 N/A 0 8
RB1 0 10 7
Only significantly mutated genes that were identified in previously published databases [44, 45] are shown. Percentages indicate frequencies of
mutated genes.
doi:10.1371/journal.pone.0129280.t002
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indel do not overlap with OncoMap and only one overlaps with OncoMap plus COSMIC sys-
tem (TP53, chr17:7579547–7579548). No indel were noted in ERBB2 and EGFR.
Finally, the 07–0120 cohort included less frequent histologic lung cancer subtypes, such as
large-cell, adenosquamous, and carcinoid. Despite the small numbers in these rare lung cancer
subtypes, SNV calling using the OncoMap database revealed previously undescribed SNV in
FGFR1, CDKN2A, RB1, JAK3, and CTNNB1 for the large-cell type, a BRAFmutation for carci-
noid, and an AKT1mutation for adenosquamous carcinoma.
Validation of SNV by RNA-Seq in the 07–0120 Patient Samples
We recently reported that RNA-seq data supports the detection of SNV called by DNA samples
[31]. Therefore, we sequenced mRNA for 23 out of the total 100 samples to validate SNV previ-
ously called by DNA-seq. These 23 DNA samples exhibited a total of 79 significant SNV in
OncoMap and the COSMIC database. 67 out of the 79 SNV (85%) were covered by at least one
RNA-seq read. We found that the power to detect these SNV is in line with the expected mu-
tant allele count (EMAC, or E) by RNA-seq, which is determined by the depth of RNA-seq and
the MAF by DNA-seq (S1 Text). The confirmation rate is 86.3%, 92.9% and 100% for E equals
to 1, 2 and 3, respectively (S2 Fig). For example, RNA-seq data was available for 8 out of 16
KRAS-hotspot-mutant samples, which were supported by either DNA or Sanger sequencing
(one SNV per sample). Of these, 7 were confirmed by RNA-seq. The confirmation rate
dropped to 6 out of 45 (13%) for SNV with E< 1. Of these 39 unconfirmed SNV (E< 1), 34
(87.2%) had DNA-seq MAF< 0.05, whereas 24 (61.5%) exhibited RNA-seq coverage
depth< 5 (S2 Fig). Of the 19 samples that were reported to contain indels, only 6 had RNA-
seq data, but with 6 reads crossing in the indel positions and ± 5-bp flanking regions. There-
fore, we were unable to confirm indels previously identified by DNA-seq.
NGS SNV Calling by Matched Germline DNA Versus Pooled Normal
DNA and CLIA-certified Laboratory Confirmation in the 11–1115 Patient
Samples
In clinical practice, a handful of NGS SNV calling algorithms have been frequently used in a
CLIA environment and without matched germline DNA [3, 6]. However, to our knowledge,
there has not been a systematic comparison between pooled normal, tumor-only variant call-
ing, and the ‘gold-standard’, matched-normal. In line with this, we have investigated the con-
sistency in SNV calling by the pooled normal, tumor-only variant calling versus matched-
normal in clinical tumor tissue samples that were prospectively collected along with matched
normal from patients with NSCLC (11–1115 cohort). To date, we have sequenced 24 tumor tis-
sues (13 FFPE, 11 SF) from patients with NSCLC for diagnostic purposes and treatment deci-
sions, and have performed independent CLIA-certified laboratory confirmation on the SNV
identified by matched normal comparisons. We were able to retrieve 69.3% (median; approx.
95CI, 58.6–72.3%) and 69.6% (median; approx. 95CI, 59.7–72.0%) on-target bases with our tar-
geted panel capture strategy of ClinSeq version 7 corresponding to tumor and matched-normal
specimens, respectively. This was an improvement from ClinSeq version 5; under this version
primer design was improved utilizing techniques suggested by the vendor (Agilent), including
duplicate coverage of difficult to sequence regions (e.g. tiling). The median of the per-sample
median RPKM was 350 (approx. 95CI, 344–353) and 347 (95CI, 344–354) for tumor and
matched-normal specimens, respectively.
S3 Table shows NGS variant calling and CLIA confirmation of mutations either identified
in the COSMIC and OncoMap databases or considered clinically important for genes with
MAF 0.05. 17 out of the total 24 tumor samples exhibited a total of 35 nonsynonymous
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SNV/stopgain/indel when compared against matched-normal. Of the 35 mutations, 16 were
selected and independently confirmed by a CLIA-certified laboratory. All SNV identified by ei-
ther calls against matched-normal or pooled normal were also in agreement with normal-free
genotyping analysis (SAMtools/BCFtools). More SNV were called against pooled normal com-
pared with matched normal (46 versus 35). Of the 11 discrepancies, 7 nonsynonymous SNV
were benign [PolyPhen-2 (PPH2) score 0.004] [46], 2 nonsynonymous SNV were possibly
damaging (PPH2<0.8), and 1 stopgain mutation had low MAF (0.06). The only probably
damaging (PPH2 = 0.999) mutation that was identified again the pooled normal as opposed to
the matched-normal was confirmed to be a germline mutation under the NCGENES project
[47].
Copy Number Variations
Technologies estimating copy number variations (CNV) prior to NGS could reliably assess
large (several Kbps to Mbps) gains or losses of DNA regions [48]. Due to the nature of NGS,
which detects genetic events with 1-bp resolution, we used flexible window size to detect not
only chromosome arm-level events commonly detected by other technologies, but also CNV at
the single gene level [49]. Fig 5, panel A, shows SNP array analysis for CNV, which was per-
formed on a subset (n = 60) of the 07–0120 tumor samples that were also subjected to TPS. In
this analysis we were able to detect previously described chromosome arm-level events, such as
1p loss and 1q gain in lung squamous and adenocarcinomas, as well as 3p loss and 3q gain in
lung squamous only [44, 45]. We then compared CNV detection tools that are either NGS-
based, such as VarScan and NGScopy, or non-NGS-based, such as SNP array. As shown in
S3 Fig, using SNP array and NGScopy we clearly saw 6p amplification in tumor ID 90 (07–0120
cohort). However, this chromosomal arm aberration was not clear when VarScan2 was applied.
Fig 5, panel B, shows examples of CNV in several chromosomes for a given tumor sample
using both NGScopy and SNP array. Similar to SNP array, NGScopy can equally detect chromo-
some arm-level CNV. Fig 5, panel B, shows different CNV patterns (e.g. copy neutrality, gain,
loss, or chromosome fragmentation) that can be detected with NGScopy in different samples.
To show that NGScopy can detect CNV at the gene level, we analyzed the 17,259-bp chro-
mosome region (chr19:10,596,796–10,614,054) that contains the 6 exons of the Kelch-Like
ECH-Associated Protein 1 (KEAP1) gene, which can undergo intragenic CNV [50] (S4 Fig).
Fig 5, panel C, shows relative copy number (in log2) of all nucleotides within each of the 6
exons of the KEAP1 gene across 64 tumor samples with available NGS data using ClinSeq4. Al-
most all tumor samples do not bear intragenic CNV across all 6 exons of the KEAP1 gene.
However, a single tumor specimen (case 90) shows loss of most exonic regions of the KEAP1
gene, except the 3’ area of exon 2 (S4 Fig). This gene-level copy number loss would have been
extremely difficult to be detected by the SNP array technology, as only two probes cover the
corresponding region. In fact, both SNP probes at locations 10,600,342 and 10,613,968, which
are within exons 1 and 4 of the KEAP1 gene, respectively, show slight gain, if any, in both loca-
tions (Fig 5, panels C, and D). Our results indicate that NGS is more sensitive in detecting in-
tragenic structural genetic variations than the SNP array.
Discussion
In this report, we present the UNC-CH experience and performance of an NGS-based TPS
assay, termed UNCseq, to analyze lung cancer samples. During the early developmental steps
of this assay, we previously showed that we can identify genetic events in DNA obtained from
cancer cell lines and SF tumors [24]. We now present methodological details, in particular the
downstream bioinformatics pipeline, and extend our experience to a well clinicopathologically
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annotated, retrospectively collected lung cancer tumor specimen collection (07–0120 tumor
cohort). We have validated important mutations in lung cancer, such as KRAS and TP53, using
Sanger sequencing in a research (i.e. non CLIA-certified) laboratory environment. In addition,
we have applied our assay along with an independent CLIA validation strategy of clinically rel-
evant SNV in a separate, prospectively collected tumor tissue cohort that not only includes
‘real-world,’ FFPE, and tumor tissue samples, but for which there is available germline DNA
(11–1115 tumor cohort). Finally, we apply our recently published RNAseq-based bioinformat-
ics method, UNCeqR [31], to validate SNV identified by DNA-seq.
Similar to other reports, we have shown that NGS is more sensitive than Sanger sequencing
in detecting somatic hot-spot SNV of the KRAS gene [51, 52]. In our dataset, the increased sen-
sitivity of NGS over Sanger sequencing was mainly attributed to its ability to detect low-fre-
quency tumor clones bearing SNV of interest, whereas stromal contamination> 50% or
coverage depth< 100x did not play a significant role. Depth of coverage in DNA sequencing is
Fig 5. DNA Copy Number Analysis Using Affymetrix Human SNP Array 6.0 Microarray (Panel A) and UNCseq (Panel B, C) or Both (Panel D) of Lung
Cancer Samples. (A) Copy number gains (red) and losses (blue) are plotted along the normal genome per each chromosome for each of the 60 completed
tumor samples in relation to tumor histology and tumor purity. (SqCC: Squamous Cell Carcinoma; SmCC: Small Cell Carcinoma; ADC/BAC:
Adenocarcinoma or Bronchio-alveolar Carcinoma; LCC: Large Cell Carcinoma; AD-SqC: Adenosquamous Carcinoma or Combined/Mixed; Carcinoid/
NSmCC: Carcinoid-Atypical, Carcinoid-Typical, or Non-small cell carcinoma) (B) Examples of chromosome-level CNV in various chromosomes (6, 14, and
19) using UNCseq in two tumor samples (27 and 90). Black dots represent the per nucleotide relative copy number ratios (CNRs) in log2. Segmentation-
derived regions of equal copy number are indicated in red lines. A red triangle at 10.6 Kbp position of chromosome 19 in the sample (ID: 90) indicates the
zoomed regions in panel C. (C) Example of small (gene-level) structural variations across exons (from 5’ to 3’) of the KEAP1 gene (RefGene ID: NM_203500)
for all (black) but one (red) tumor samples. Markers from the Genome-Wide Human SNP Array 6.0 corresponding to the chromosome area where KEAP1
gene is located are highlighted in red triangles. (D) Boxplot analysis illustrating the SNP array signals at these two markers in C. Signals of tumor sample 90
are in red.
doi:10.1371/journal.pone.0129280.g005
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one of the most important parameters affecting cost, computational time, and ultimately speed
to report results back to the patient [53]. Recent reports have recommended that> 200x cover-
age is required to maintain high sensitivity in detecting low frequency base substitutions [3]
and> 30x coverage was sufficient to detect mutations at allele fractions 0.2 with approxi-
mately 90% sensitivity [35]. In the case of detecting low-MAF KRAS hotspot SNV using
UNCseq, this was indeed true; none of the 4 samples that exhibited approximately or less than
5%MAF (Fig 3C) had NGS coverage less than 100x. Nevertheless, in our study, we show that
we were successful in achieving at least 50x coverage, the minimum requirement for reliable
SNV calling [54], by loading 8 samples per lane for nearly all tumor samples, based on our TPS
strategy and the performance of the HiSeq 2000 instrument.
Availability of germline DNA would increase analytical sensitivity and distinguish between
inherited variant and somatic SNV [55], and lack of same-patient germline DNA significantly
affects frequency of calling SNV. While the lack of germline DNA information is a weakness
for the SNV calling in the 07–0120 tumor cohort, it is a common challenge faced in clinical
cancer research and is currently widely used in every day clinical practice [3]. Nevertheless,
there is insufficient knowledge about direct comparison between the gold standard (i.e. germ-
line DNA control) with other mutation calling strategies, such SNV calling against pooled nor-
mal DNA or normal-free genotyping analysis. At least for SNV previously reported in known
mutation databases, such as OncoMap and COSMIC, all mutations detected in the 24 tumor
specimens using the germline DNA comparison algorithm were also detected in the exact same
samples that were compared against pooled normal DNA. Furthermore, all mutations detected
using the pooled normal DNA strategy were consistent with normal-free genotyping analysis.
However, non-germline DNA-based mutation calling strategies were associated with over-re-
porting of SNV. From this direct comparison between these two SNV calling strategies (i.e.
germline DNA versus pooled normal DNA), the ‘price’ paid for the lack of germline DNA in-
formation does not appear to be detrimental; two of the over-reported SNV using the pooled
normal DNA strategy did not have significant impact in protein function, as assessed by the
PolyPhen-2 algorithm, with all its limitations [56]. However, the third over-reported SNV in
the 11–1115 cohort was clinically important because it was a germline mutation, which could
not be distinguished from somatic mutations by the lack of matched normal samples.
Developing methodologies for SNV calling in tumor tissues lacking same-patient germline
DNA using prior knowledge from mutation databases for diagnostic purposes, but not for pure
discovery research, are important. Our SNV calling algorithm that was applied to the 07–0120
tumor cohort reveals that the more stringent the SNV database is, the lower the frequency of
SNV calls. In particular, using the combined sequence information from both OncoMap and
COSMIC databases for the 07–0120 tumor cohort, the frequency of SNV calls using our algo-
rithm was not significantly different compared to large, published lung cancer datasets with
available germline DNA [44, 45]. We also found that the significantly higher frequency of SNV
calling using less stringent databases led to a significantly higher identification of clinically un-
important SNV (e.g., synonymous) or more non-synonymous SNV of unknown clinical signif-
icance. These findings from the 07–0120 tumor cohort, as well as the over-reporting of SNV
that do not have significant impact in protein function using the pooled normal DNA as com-
pared with the matched normal DNA in the 11–1115 tumor cohort, suggest that lack of same-
patient germline DNA does not significantly affect frequency of calling of detrimental SNV.
Among other potential applications, UNCeqR allows for lack of germline DNA and pro-
vides the basis for additional validation of SNV called by DNA-seq [31]. Although tumor puri-
ty was not a particular challenge in our dataset (12% of tumor samples exhibited 40% tumor
content), RNA-seq was unable to validate all mutations detected from DNA-seq due to low
RNA depth and/or low DNAMAF. It is quite possible that higher confirmation rates might
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have been achieved if we had greater depth of RNA-seq. Also, due to the current study’s explor-
atory nature of RNA-seq as an independent SNV validation tool, we did not expand our inves-
tigation into using RNA-seq as an independent SNV detection algorithm for our samples.
Nevertheless, given our prior analysis by methods that integrate same-tumor RNA and DNA-
seq data, such as UNCeqR, we envision that identifying clinically important, ‘driver’ SNV in
clinical specimens by combining RNA and DNA sequencing might enhance sensitivity and
specificity and possibly lower overall cost.
While the clinical significance of large copy number variations in cancer is well established
[57], the role of gene-level or even smaller scale (i.e.<1 Kbp) alterations in tumor develop-
ment, progression, and treatment is largely unknown. Given the 1-bp resolution of NGS, devel-
opment of bioinformatics methods to detect CNV, in particular structural DNA
changes< 1Kbp, is appealing. Furthermore, data generated by TPS are particularly challenging
to extrapolate for genome-wide CNV detection given the de facto uneven coverage across the
genome. It is therefore not surprising that applications of TPS to the analysis of CNV are un-
derdeveloped [58, 59]. In line with this unmet need, we have developed a CNV detection meth-
od that depends on the coverage depth in a tumor sample in comparison with pooled germline
DNA, termed NGScopy. This method takes into account both on-target and off-target sequence
reads, which are expected to be randomly distributed across the gene panel and the entire ge-
nome, respectively. Therefore, while these off-target reads do not contribute to SNV calling,
they are valuable to compute genome-wide copy number events. Finally, this method relies on
flexible window size as well as the distribution of the coverage depth in normal samples. Over-
all, we show that NGScopy detects large-scale CNV, similar to those identified by the genome-
wide Affymetrix Human SNP Array 6.0, and performs better for TPS data compared to popular
CNV NGS-based algorithm, such as VarScan. However, NGS, by having greatly improved res-
olution over SNP array, was superior in terms of detecting small-scale intragenic CNV. We
propose that CNV detection tools using NGS data, such as NGScopy, could supplement CNV
detection by SNP arrays, especially for the largely unexplored evaluation of small-scale se-
quencing (e.g., TPS) in cancer.
Despite the strength of our study to compare our NGS-based analysis with gold-standard
approaches, such as Sanger sequencing and SNP arrays, there are several limitations. First, and
in particular for the 07–0120 tumor cohort, we used the less expensive and more time-efficient
single-end sequencing, as opposed to the more established paired-end sequencing. Single-end
reads may pose computational challenges in the differential diagnosis and estimation of the
percentage of PCR when compared to true biological duplicate reads [60]. Therefore, removal
of duplicates may on one hand limit overestimation of true coverage depth, but may on the
other hand eliminate other true alignments during further downstream analysis. In fact, for the
11–1115 tumor cohort, we have currently incorporated paired-end sequencing in routine se-
quencing as part of the UNCseq project. Second, like any NGS-based assay that is currently im-
plemented, refinement and optimization of UNCseq assay is a moving target in several areas
ranging from the number and type of genes to be analyzed, the targeted exome capture, the se-
quencing strategy (single-end versus paired end), and the downstream bioinformatics pipeline
(S2 Table). In our study this is more apparent in the analysis of the 07–0120 tumor cohort for
which two different gene lists were used (ClinSeq version 4 and 5). As the gene list is further
updated, future ClinSeq versions are planned to include additional probes to also capture par-
ticular recurrent structural DNA alterations that we could not previously identify, such as ge-
nome rearrangements that in fact are frequently observed in lung cancer [61, 62].
In summary, we present the performance of our NGS-based laboratory assay, termed
UNCseq, to detect genetic aberrations (SNV, indel, and CNV) in a large number of lung cancer
specimens that were collected in our institution. We show that when compared to traditional
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methods, such as Sanger sequencing and the genome-wide Affymetrix Human SNP Array 6.0,
TPS is even more sensitive in mutation calling at a 50-100x coverage, and may detect intragenic
CNV that are not identified by SNP arrays. We further report that the majority of clinically rel-
evant genes that were found in our study to be mutated were also observed in large previously
published datasets [40, 41]. We provide direct comparison between germline and non-germline
DNA-based mutation calling strategies using the UNCseq assay, as well as independent CLIA
validation of several mutations in a separate tumor tissue cohort (11–1115). We believe that
our UNCseq methodology is standardized, robust, and can provide valuable genetic informa-
tion about clinically actionable mutations in a cost-effective and time-efficient manner, if
paired with validation in a CLIA-certified laboratory.
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S1 Fig. SNV and indel calling in lung cancer specimens using the UNCseq assay. (A) SNV
listed in the OncoMap annotation (version 4) plus the COSMIC database (“liberal” SNV). Per-
centage, actual number of significantly mutated genes, and particular SNV types [nonsynon-
ymous (nonsense, missense) and synonymous] are shown for each tumor sample in relation to
its tumor histology and tumor purity and colored differently for each of the two SNV databases
(OncoMap, COSMIC). (B) Indel calling was performed without refining using OncoMap and
COSMIC database.
(PDF)
S2 Fig. Validation of SNV that were identified by DNA-seq and were covered by at least
one RNA-seq read. The coverage depth by RNA-seq and the MAF by DNA-seq are shown, on
logarithmic-scale axes, for each SNV of OncoMap and COSMIC. Circles and triangles indicate
confirmed and unconfirmed SNV, respectively. KRAS, TP53, and EGFR which were found to
be most frequently mutated in our sample set are highlighted with orange, purple, and blue, re-
spectively. Dashed lines indicate expected mutant allele count (E) equaling to 1, 2 and 3.
(PDF)
S3 Fig. Comparison of copy number variation calling using VarScan (A), NGScopy (B), and
SNParray (C) on chromosome 6 for patient ID 90 (07–0120 cohort). Gray dots indicate the
log2 copy number ratio of the tumor against the pooled normal per each window detected by
each computational program. NGScopy and SNParray show clear 6p amplification compared
with VarScan. The y-axis was truncated to [-3, 3] as we zoom in on a majority (99.42%, 100%,
99.96%, respectively) of the data for comparison.
(PDF)
S4 Fig. Targeted panel sequencing of the KEAP1 gene for patient ID 90 (07–0120 tissue co-
hort). Panels show an adapted Omicsoft's genome browser view (http://www.omicsoft.com/
genome-browser/). The chromosome position and the structure of the KEAP1 isoforms of
NCBI RefGene is shown in (A). The depth of coverage using TPS for patient ID 90 (bottom)
against the pooled normal (top) is shown in (B). Read counts were normalized to Reads Per
Ten Million (RPTM) reads per library. Red corresponds to covered exon regions and purple
corresponds to covered intron/intergenic regions.
(PDF)
S1 Table. List of genes that were included in ClinSeq versions 4, 5 and 7 of the UNCseq
project.
(DOCX)
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S2 Table. Key differences of the UNCseq sequencing, bioinformatics pipeline, and valida-
tion of tissue samples between the 07–0120 and 11–1115 cohort. Abbreviations: SF, snap-
frozen; FFPE, formalin-fixed paraffin-embedded; bp, base pair; PCR, polymerase chain reac-
tion; CLIA, clinical laboratory improvement amendments.
(DOCX)
S3 Table. List of mutations identified in the 24 tumor tissue samples collected as part of the
11–1115 tissue cohort using three methods to call mutations (matched normal, pooled nor-
mal, and normal free variant calling). Abbreviations: SF, snap-frozen; FFPE, formalin-fixed
paraffin-embedded; SNV, single-nucleotide variations; CLIA, clinical laboratory improvement
amendments; SOC, standard of care assays used by CLIA-certified Molecular Pathology labo-
ratories to report mutations for clinical use; PPH2, PolyPhen 2; MAF, mutant allele frequency;
Nonsyn., Nonsynonymous; Nonframe., Nonframeshift; Frame., Frameshift; ins., insertion; del.,
deletion; dam., damage.
(DOCX)
S1 Text. Definitions for depth of coverage (or read depth), breath of coverage, on-target
rate, and expected mutant allele count.
(DOCX)
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